Skip to main content
OpenTrials
Completed

NCT Number: NCT02187575

Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers

Study to investigate the bioequivalence between 10 mg tablets (test drug) and 10 mg capsules (reference drug) of meloxicam (UHAC 62 XX) after 7-day administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 20 and <= 35 years
  • Weight: Body Mass Index >= 18.5 and < 25
  • Subjects who are judged by the investigator to be appropriate as the subjects of the study based on results of screening test
  • Subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent

Exclusion criteria

  • History of gastrointestinal ulcer or surgery of gastrointestinal tract (except appendectomy)
  • History of hypersensitivity to UHAC 62 XX and/or salicylate (aspirin etc.) and/or Non-steroidal anti-inflammatory drugs (NSAIDs)
  • History of aspirin induced asthma (bronchial asthma induced by NSAIDs)
  • History of bleeding tendency
  • History of alcohol or drug abuse
  • Participation to another trial with an investigational drug within 4 months prior to the trial
  • Whole blood donation more than 400 ml within 3 months prior to the trial
  • Whole blood donation more than 100 ml within 1 month prior to the trial
  • Donation of constituent of blood of more than 400 ml within 1 month prior to the trial
  • Any medication which might influence the results of the trial within 10 days prior to the trial
  • Excessive physical activities within 7 days prior to the trial
  • Alcohol drinking within 3 days prior to the trial
  • History of orthostatic hypotension, fainting spells or blackouts
  • Other than above, those who are judged by the investigator to be inappropriate as the subjects of the study

Treatment and study plan

UHAC 62 XX tablet

Drug

UHAC 62 XX capsule

Drug

Primary outcomes

  1. Cmax (maximum observed concentration of the analyte in plasma)

    Time frame: up to day 8

  2. AUC 0-τ (Area under the concentration time curve in plasma from zero time to 24 hours after 7-day administration)

    Time frame: up to day 8

Secondary outcomes

  1. Tmax (Time to reach Cmax)

    Time frame: up to day 8

  2. T1/2 (Terminal half-life in plasma)

    Time frame: up to day 8

  3. MRT 0-τ (Mean residence time in the body after 7-day administration)

    Time frame: up to day 8

  4. Cτ (Concentration of the analyte in plasma 24 hours after 7-day administration)

    Time frame: up to day 8

  5. Number of patients with adverse events

    Time frame: up to 20 days after final administration

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Bioequivalence Study of UHAC62XX 10 mg Tablets Compared With 10 mg Capsules Following Multiple Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)

Important dates

Study start
2002
Primary completion
2002
First posted
Jul 11, 2014
Registry last updated
Jul 14, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.